NCT04796467 is a Phase 2, PHASE3 clinical trial of 68Ga-PSMA-617 in Prostate Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT04796467?

NCT04796467 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04796467?

Interventions in NCT04796467: 68Ga-PSMA-617, 68Ga-P16-093.

What condition does NCT04796467 study?

NCT04796467 studies Prostate Cancer.

Is NCT04796467 still recruiting?

NCT04796467 is currently status unknown. Last updated 9 August 2022.

Last reviewed 2022-08-09 · How we verify

NCT04796467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients

Status unknown Phase 2, PHASE3 Last updated 9 August 2022

What this trial tests

Phase 2, PHASE3 trial testing 68Ga-PSMA-617 in Prostate Cancer in 50 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
1 August 2021

1 October 2022

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	1 October 2020
Primary completion	1 August 2021
Estimated completion	1 October 2022
Sites	1 location across China

Drugs / interventions tested

68Ga-PSMA-617 — full drug profile →
68Ga-P16-093 — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 90, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the widely studied 68Ga-PSMA-617. This pilot study was prospectively designed to evaluate the early dynamic distribution of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-617 in the same group of prostate cancer patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Head-to-head comparison of [<sup>68</sup> Ga]Ga-P16-093 and [<sup>68</sup> Ga]Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients.
Wang G, Hong H, Zang J, Liu Q, et al · · 2022 · cited 17× · PMID 34557930 · DOI 10.1007/s00259-021-05539-1
Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.
Ng TSC, Gao X, Salari K, Zlatev DV, et al · · 2021 · cited 4× · PMID 34395293 · DOI 10.3389/fonc.2021.722277
Head-to-Head Comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in Dynamic PET/CT Evaluation of the Same Group of Recurrent Prostate Cancer Patients
Wang G, Hong H, Zang J, Liu Q, et al · · 2021 · DOI 10.21203/rs.3.rs-739096/v1

Verify or expand the search:

Other trials of 68Ga-PSMA-617

Trials testing the same drug.

NCT05841992 — Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients · Phase 2, PHASE3 · unknown

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04796467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 9 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04796467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing